Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Cannon-Smith

Urogynecology and Reconstructive Pelvic Surgery Arlington, TX Medical Doctor

NPI 1942297569 CMS profile 314769

5005 S Cooper St Ste 250, Arlington, TX 76017

Open in the dashboard

General payments

$28,879

271 records reported · program years 2019–2025

Research payments

$2,096

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Cannon-Smith of Arlington, TX is reported in the CMS Open Payments database as having received $28,879 across 271 general payments and $2,096 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,394 22
2024 General $2,933 40
2023 General $3,446 46
2022 General $1,627 37
2022 Research $2,096 2
2021 General $5,284 38
2020 General $2,927 34
2019 General $11,268 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Cannon-Smith
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Tracy Cannon-Smith were reported at $1,394. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Tracy Cannon-Smith Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $11,268 $799 $319–$2,013 $163
2020 $2,927 $384 $158–$1,360 $114
2021 $5,284 $641 $247–$2,515 $132
2022 $1,627 $843 $347–$2,794 $149
2023 $3,446 $819 $308–$2,302 $160
2024 $2,933 $882 $306–$2,459 $164
2025 $1,394 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Caldera Medical, Inc $9,418 10 payments
  2. Axonics Modulation Technologies, Inc. $6,085 29 payments
  3. Medtronic, Inc. $5,347 51 payments
  4. Medtronic USA, Inc. $3,539 25 payments
  5. Astellas Pharma US Inc $482 28 payments
  6. AbbVie, Inc. $442 20 payments
  7. Boston Scientific Corporation $439 9 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $383 23 payments
  9. Valencia Technologies Corporation $328 9 payments
  10. Janssen Biotech, Inc. $233 4 payments
  11. Other $2,183 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $12,100 3 payments
  2. Food and Beverage $9,757 241 payments
  3. Travel and Lodging $4,039 16 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,265 2 payments
  5. Gift $580 7 payments
  6. Grant $114 1 payment
  7. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. Desara $9,418 10 payments
  2. Vertessa $8,800 1 payment
  3. INTERSTIM Sacral Nerve Stimulation $3,477 40 payments
  4. Axonics r-SNM System $3,446 6 payments
  5. Axonics $2,549 21 payments
  6. Bulkamid $2,138 13 payments
  7. INTERSTIM Sacral Nerve Stimulation $1,156 21 payments
  8. ALTAVIVA $822 7 payments
  9. MYRBETRIQ $442 26 payments
  10. Nubeqa $383 23 payments
  11. Other $4,717 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,096 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,219

Median for Urology: 1,053

Drug cost

$589,091

Median for Urology: $101,464

Branded share of claims

59.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 610 $432,239
Gemtesa Vibegron Brand 63 $50,969
Mirabegron Er Mirabegron Brand 85 $46,826
Estradiol Generic 254 $18,403
Trospium Chloride Er Trospium Chloride Brand 56 $9,855
Methenamine Hippurate Generic 77 $7,731
Solifenacin Succinate Generic 100 $4,965
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 77 $3,358
Trospium Chloride Generic 61 $3,105
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 29 $2,749

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$337,972

Of which drugs: $16,244

Medicare patients

650

Average age 77

Services billed

10,405

550 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 35%
Chronic kidney disease 31%
Depression 29%
Ischemic heart disease 27%
Osteoporosis 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 24 3,300 $16,225

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$75 — 3,300
ERLEADA
$58 — —
AKEEGA
$58 — —
Nubeqa
$33 — —
Xofigo
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record